Holen Sie sich die Stockscreener-App
6.24
0.32%
-0.02
Handel nachbörslich:
6.25
0.010
+0.16%
Cartesian Therapeutics Inc Aktie (RNAC) Neueste Nachrichten
Trust linked to Cartesian Therapeutics (RNAC) converts preferred into common - stocktitan.net
Trust linked to RNAC holder Kalayoglu converts preferred into 758,001 common shares - stocktitan.net
If You Invested $1,000 in Cartesian (RNAC) - stocktitan.net
Near-20% holder updates Cartesian Therapeutics (RNAC) stake and board role - stocktitan.net
Cartesian Therapeutics Announces New Employment Inducement Grants - The Manila Times
Cartesian gives two new hires stock options at $6.39 a share - stocktitan.net
RNAC Technical Analysis & Stock Price Forecast - Intellectia AI
Published on: 2026-04-01 20:53:55 - baoquankhu1.vn
Big Money Moves: Should I invest in Cartesian Therapeutics Inc before earningsEarnings Summary Report & Smart Allocation Stock Tips - baoquankhu1.vn
Inflation Data: Does Cartesian Therapeutics Inc have declining or rising EPSMarket Weekly Review & Technical Buy Zone Confirmation - baoquankhu1.vn
Merger Talk: Will Cartesian Therapeutics Inc outperform the market in YEAR2026 EndofYear Setup & Entry Point Confirmation Signals - baoquankhu1.vn
Cartesian Therapeutics board member Murat Kalayoglu to resign effective March 31 - Investing.com UK
Cartesian Therapeutics Announces Board Member Murat Kalayoglu Resignation - TipRanks
Cartesian Therapeutics board member Murat Kalayoglu to resign effective March 31 By Investing.com - Investing.com South Africa
Murat Kalayoglu to Resign from Cartesian Board, Leaving Science & Technology Committee - TradingView
Board member Murat Kalayoglu to leave Cartesian Therapeutics (RNAC) board March 31, 2026 - stocktitan.net
Treasury Yields: Why is Cartesian Therapeutics Inc stock going down2026 Volume Leaders & Safe Capital Investment Plans - baoquankhu1.vn
Energy Moves: Is Cartesian Therapeutics Inc benefiting from interest rate changesMarket Activity Recap & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Aug Patterns: Will Cartesian Therapeutics Inc outperform during market ralliesEarnings Summary Report & Growth Oriented Trading Recommendations - baoquankhu1.vn
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Trading Action: Will Cartesian Therapeutics Inc outperform during market ralliesPortfolio Gains Report & High Accuracy Buy Signal Tips - baoquankhu1.vn
Swing Trade: Is Cartesian Therapeutics Inc benefiting from interest rate changesQuarterly Profit Summary & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Published on: 2026-03-26 03:38:41 - baoquankhu1.vn
Insiders' US$1.73m Investments In Red Following Cartesian Therapeutics' US$29m Dip In Market Value - simplywall.st
Published on: 2026-03-22 15:23:24 - baoquankhu1.vn
Investment Review: Is Cartesian Therapeutics Inc showing insider buyingWeekly Gains Summary & Risk Controlled Daily Plans - baoquankhu1.vn
Squarepoint Ops LLC Acquires Significant Stake in Cartesian Therapeutics Inc - GuruFocus
Bear Alert: Why is Cartesian Therapeutics Inc stock going downPrice Action & AI Driven Stock Reports - baoquankhu1.vn
Cartesian Therapeutics (RNAC) director Michael Singer gifts 6,555 shares - Stock Titan
Squarepoint entities disclose multi-affiliate stakes in Cartesian Therapeutics (RNAC) — 8.3% each - Stock Titan
Published on: 2026-03-13 09:11:18 - baoquankhu1.vn
RNAC’s Descartes-08 Moves Toward Phase 2 in Rare Muscle Disease: What Investors Should Watch - TipRanks
Cartesian Therapeutics (NASDAQ:RNAC) Receives “Outperform” Rating from Wedbush - Defense World
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Cartesian Therapeutics (RNAC) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Design Therapeutics (DSGN) and Cartesian Therapeutics (RNAC) - The Globe and Mail
Growth Recap: Does Cartesian Therapeutics Inc have declining or rising EPS2026 Retail Activity & Stock Portfolio Risk Management - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: MacroGenics (MGNX) and Cartesian Therapeutics (RNAC) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Myasthenia Gravis Market: Pharma Pipeline Fuels Rapid Expansion by 2034 – DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen Research & Development, LLC - Barchart
Wedbush Reiterates 'Outperform' Rating on RNAC | RNAC Stock News - GuruFocus
Cantor Fitzgerald upgrades Cartesian Therapeutics (RNAC) - MSN
Cartesian Therapeutics' (RNAC) "Outperform" Rating Reiterated at Wedbush - marketbeat.com
Cartesian Therapeutics (NASDAQ:RNAC) Upgraded to “Overweight” at Cantor Fitzgerald - Defense World
BTIG reiterates Buy on Cartesian Therapeutics stock, $44 target By Investing.com - Investing.com Canada
Cartesian Therapeutics Reports 2025 Financial Results, Advances Descartes-08 Cell Therapy in Autoimmune Diseases and Myasthenia Gravis Phase 3 Trial - Minichart
Mizuho reiterates Cartesian Therapeutics stock rating on trial progress By Investing.com - Investing.com Canada
Cartesian Therapeutics (RNAC) Upgraded to Overweight by Cantor F - GuruFocus
Today's Analyst Ratings: Needham Reiterates Buy Rating for RNAC - GuruFocus
Cartesian Therapeutics (NASDAQ:RNAC) Receives Buy Rating from Needham & Company LLC - MarketBeat
Cartesian Therapeutics, Inc. 2025 Annual Report – Pipeline, Clinical Trials, Regulatory Approvals, and Competitive Landscape - Minichart
Cantor Fitzgerald Upgrades Cartesian Therapeutics (NASDAQ:RNAC) to Overweight - MarketBeat
Cartesian Therapeutics Inc expected to post a loss of 85 cents a shareEarnings Preview - TradingView
Cartesian Therapeutics posts full year 2025 financial results and issues business update - Traders Union
Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Cartesian Therapeutics (NASDAQ:RNAC) Issues Earnings Results, Misses Estimates By $0.56 EPS - MarketBeat
Cartesian Therapeutics 2025 10-K: Revenue $2.8M, Net Loss $130.3M - TradingView
[8-K] Cartesian Therapeutics, Inc. Reports Material Event | RNAC SEC FilingForm 8-K - Stock Titan
Cartesian backs MG cell therapy trials with $126.9M cash runway into 2027 - Stock Titan
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):